Interpace Biosciences Announces First Quarter 2020 Financial and Business Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Interpace Biosciences (IDXG) Misses Q1 EPS by $1.09, Revenues Beat
June 25, 2020 5:03 PM EDTInterpace Biosciences (NASDAQ: IDXG) reported Q1 EPS of ($2.31), $1.09 worse than the analyst estimate of ($1.22). Revenue for the quarter came in at $9.2 million versus the consensus estimate of $8.93 million.
Net Revenue for the first quarter of 2020 was $9.2 million, an increase of 53% from the prior year first quarter, which did not include Pharma services revenues.Gross Profit was 34% as compared to 56% in the first quarter of 2019; this decrease was due principally to the lower margins associated with Pharma services in 2020.Loss from Continuing Operations was $(6.2) million as compared to $(3.4)... More